EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
[HTML][HTML] 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and …
Context 68 Gallium prostate-specific membrane antigen (PSMA) ligand 68 Ga-HBED-CC-
PSMA (68 Ga-PSMA) is a promising radiotracer for positron emission tomography …
PSMA (68 Ga-PSMA) is a promising radiotracer for positron emission tomography …
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C Parker, E Castro, K Fizazi, A Heidenreich… - Annals of …, 2020 - annalsofoncology.org
Subclinical prostate cancer is common in men> 50 years. Population-based screening of
men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been …
men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been …
Optimum imaging strategies for advanced prostate cancer: ASCO guideline
PURPOSE Provide evidence-and expert-based recommendations for optimal use of
imaging in advanced prostate cancer. Due to increases in research and utilization of novel …
imaging in advanced prostate cancer. Due to increases in research and utilization of novel …
Bone metastases
RE Coleman, J Brown, I Holen - Abeloff's clinical oncology, 2020 - Elsevier
Bone metastasis is a major cause of morbidity in persons with cancer. Complications include
pain, impaired mobility, pathological fracture, spinal cord compression, cranial nerve …
pain, impaired mobility, pathological fracture, spinal cord compression, cranial nerve …
Positron emission tomography (PET) in oncology
A Gallamini, C Zwarthoed, A Borra - Cancers, 2014 - mdpi.com
Since its introduction in the early nineties as a promising functional imaging technique in the
management of neoplastic disorders, FDG-PET, and subsequently FDG-PET/CT, has …
management of neoplastic disorders, FDG-PET, and subsequently FDG-PET/CT, has …
Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years
Abstract Background Prostate cancer (PCa) patients with lymph node recurrence after
radical prostatectomy (RP) are usually managed with androgen-deprivation therapy. Despite …
radical prostatectomy (RP) are usually managed with androgen-deprivation therapy. Despite …
Clinical PET imaging in prostate cancer
KL Wallitt, SR Khan, S Dubash, HH Tam, S Khan… - Radiographics, 2017 - pubs.rsna.org
Prostate cancer is the second most common cancer in men worldwide, with a wide spectrum
of biologic behavior ranging from indolent low-risk disease to highly aggressive castration …
of biologic behavior ranging from indolent low-risk disease to highly aggressive castration …
A review of imaging methods for prostate cancer detection: supplementary issue: image and video acquisition and processing for clinical applications
Imaging is playing an increasingly important role in the detection of prostate cancer (PCa).
This review summarizes the key imaging modalities–multiparametric ultrasound (US) …
This review summarizes the key imaging modalities–multiparametric ultrasound (US) …
Biodistribution of [68Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions
V Prasad, IG Steffen, G Diederichs… - Molecular imaging and …, 2016 - Springer
Purpose The aim of this study was to determine the physiological and pathophysiological
biodistribution of [68 Ga] PSMA-HBED-CC (PSMA-11)([68 Ga] PSMA) in patients with …
biodistribution of [68 Ga] PSMA-HBED-CC (PSMA-11)([68 Ga] PSMA) in patients with …